Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...
Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...
Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports.
Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. Get Wall Street's Hottest Chart Every ...
Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on treatments for serious immunological diseases, announced that its management will present at the 43rd Annual J.P ...
Vera Therapeutics BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(RTTNews) - Vera Therapeutics (VERA), a late clinical-stage biotechnology company, announced on Wednesday that it has granted inducement awards to six new employees. The awards consist of non ...
Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback